thromboxanes has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| De La Rosa, X; Gracia Banzo, R; Regidor, PA; Rizo, JM; Santos, FG; Silva, RS | 1 |
| Bartimoccia, S; Bufano, M; Cammisotto, V; Carnevale, R; Castellani, V; Ceccarelli, G; Coluccia, A; D'Amati, G; Frati, G; Leopizzi, M; Loffredo, L; Maria Mastroianni, C; Nocella, C; Oliva, A; Pignatelli, P; Pugliese, F; Sciarretta, S; Silvestri, R; Turriziani, O; Venditti, M; Violi, F | 1 |
2 other study(ies) available for thromboxanes and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Acute severe SARS COVID-19 patients produce pro-resolving lipids mediators and eicosanoids.
Topics: Acute Disease; Adult; Case-Control Studies; Chromatography, High Pressure Liquid; COVID-19; Eicosanoids; Fatty Acids, Unsaturated; Humans; Inflammation Mediators; Male; SARS-CoV-2; Severity of Illness Index; Tandem Mass Spectrometry; Thromboxanes | 2021 |
Toll-Like Receptor 4-Dependent Platelet-Related Thrombosis in SARS-CoV-2 Infection.
Topics: Antibodies, Monoclonal; Blood Platelets; COVID-19; Cross-Sectional Studies; Humans; SARS-CoV-2; Thrombosis; Thromboxanes; Toll-Like Receptor 4 | 2023 |